ACA
AMED

Ackerman Capital Advisors’s Amedisys AMED Stock Holding History

Ackerman Capital Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,000
Closed -$245K – 115
2021
Q2 		$245K Hold
1,000
– – 0.06% 105
2021
Q1 		$265K Hold
1,000
– – 0.06% 104
2020
Q4 		$293K Sell
1,000
-36
-3% -$9.23K 0.07% 90
2020
Q3 		$245K Hold
1,036
– – 0.07% 96
2020
Q2 		$206K Buy
+1,036
New +$193K 0.06% 113

Other funds holding AMED

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ackerman Capital Advisors's AMED Position: Q3 2021 in Review

Ackerman Capital Advisors sold out of Amedisys (AMED) in Q3 2021, closing a stake of 1,000 shares — an estimated $245K sold.

Ackerman Capital Advisors first reported a position in AMED in Q2 2020 and held it in 5 quarters. The position peaked at $293K in Q4 2020. 352 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

  • Ackerman Capital Advisors reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
  • Ackerman Capital Advisors sold 1,000 Amedisys shares in Q3 2021, an estimated $245K.
  • Ackerman Capital Advisors first reported a position in Amedisys in Q2 2020 and held it in 5 quarters.
  • Ackerman Capital Advisors's Amedisys position peaked at $293K in Q4 2020.
  • 352 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Ackerman Capital Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.